On August 8, the third day of bidding for the Concord Biotech initial public offering (IPO), bids for 32.76 crore equity shares were put against the IPO size of 1.46 crore shares, resulting in an aggregate subscription of 22.36 times by 3.34 PM.
High net worth individuals (HNIs) and retail investors responded positively to the IPO, subscribing 16.67 times and 3.56 times, respectively. Employees were especially enthusiastic, bidding 23.37 times their quota. A total of 59.53% share was subscribed by qualified institutional buyers.
Concord Biotech issued 10,000 equity shares in the IPO to its employees, providing them at a Rs 70 per share discount from the final offer price. Half of the offer size is allocated to qualified institutional buyers, 15% to high net worth individuals, and the remaining 35% to ordinary investors, according to the allocation structure.
The Concord Biotech IPO is priced between Rs 705 and Rs 741 per equity share.
Concord Biotech, funded by RARE Trusts, plans to raise Rs 1,551 crore via this IPO.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.